Treatment of pulmonary tuberculosis.
D002207:Capreomycin / Q000009:adverse effects; D002478:Cells, Cultured; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D003523:Cycloserine / Q000009:adverse effects; D003863:Depression / Q000139:chemically induced; D004342:Drug Hypersensitivity; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000009:adverse effects / Q000627:therapeutic use; D005500:Follow-Up Studies; D006760:Hospitalization; D006801:Humans; D007538:Isoniazid / Q000009:adverse effects / Q000627:therapeutic use; D007612:Kanamycin / Q000009:adverse effects; D007674:Kidney Diseases / Q000139:chemically induced; D009902:Optic Neuritis / Q000139:chemically induced; D010353:Patient Education as Topic; D012293:Rifampin / Q000627:therapeutic use; D013307:Streptomycin / Q000009:adverse effects; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000601:surgery
D002207:Capreomycin; D007612:Kanamycin; D004977:Ethambutol; D003523:Cycloserine; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin